## Firas El Chaer

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2201144/publications.pdf

Version: 2024-02-01

1163117 888059 24 307 8 17 citations h-index g-index papers 24 24 24 653 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	MRD in ALL: Optimization and Innovations. Current Hematologic Malignancy Reports, 2022, 17, 69-81.	2.3	6
2	Immune effector cell–associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes. Neuro-Oncology, 2021, 23, 112-121.	1.2	53
3	Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. Transplantation and Cellular Therapy, 2021, 27, 6-20.	1.2	45
4	FLT3-ITD Allelic Burden and Acute Promyelocytic Leukemia Risk Stratification. Biology, 2021, 10, 243.	2.8	1
5	Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML. Blood Advances, 2021, 5, 1757-1759.	5.2	9
6	Pegaspargase in Practice: Minimizing Toxicity, Maximizing Benefit. Current Hematologic Malignancy Reports, 2021, 16, 314-324.	2.3	9
7	Variant Acute Promyelocytic Leukemia Presenting Without Auer Rods Highlights the Need for Correlation with Cytogenetic Data in Leukemia Diagnosis. Laboratory Medicine, 2021, , .	1.2	O
8	Increased body mass index is a risk factor for acute promyelocytic leukemia. EJHaem, 2021, 2, 33-39.	1.0	5
9	Treatment of acute leukaemia in adult Jehovah's Witnesses. British Journal of Haematology, 2020, 190, 696-707.	2.5	1
10	Peripheral blood blast rate of clearance is an independent predictor of clinical response and outcomes in acute myeloid leukaemia. British Journal of Haematology, 2020, 188, 881-887.	2.5	7
11	Clustered incidence of adult acute promyelocytic leukemia in the vicinity of Baltimore. Leukemia and Lymphoma, 2020, 61, 2743-2747.	1.3	O
12	Comparison of High-Dose Cytarabine, Mitoxantrone, and Pegaspargase (HAM-pegA) to High-Dose Cytarabine, Mitoxantrone, Cladribine, and Filgrastim (CLAG-M) as First-Line Salvage Cytotoxic Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia. Journal of Clinical Medicine, 2020, 9, 536.	2.4	11
13	MLL-Rearranged Acute Lymphoblastic Leukemia. Current Hematologic Malignancy Reports, 2020, 15, 83-89.	2.3	50
14	Severe dysautonomia as a manifestation of neurotoxicity after <scp>CARâ€₹</scp> cell therapy for diffuse large <scp>Bâ€cell</scp> lymphoma. American Journal of Hematology, 2020, 95, E146-E148.	4.1	4
15	Cryptic ETV6–PDGFRB fusion in a highly complex rearrangement of chromosomes 1, 5, and 12 due to a chromothripsis-like event in a myelodysplastic syndrome/myeloproliferative neoplasm. Leukemia and Lymphoma, 2019, 60, 1304-1307.	1.3	8
16	The Reply. American Journal of Medicine, 2019, 132, e668.	1.5	0
17	Relapsed Philadelphia Chromosome-Positive Pre-B-ALL after CD19-Directed CAR-T Cell Therapy Successfully Treated with Combination of Blinatumomab and Ponatinib. Acta Haematologica, 2019, 141, 107-110.	1.4	14
18	Refractory postallogeneic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab. American Journal of Hematology, 2019, 94, E216-E219.	4.1	23

#	Article	IF	CITATION
19	Vaccination in the Adult Patient Infected with HIV: A Review of Vaccine Efficacy and Immunogenicity. American Journal of Medicine, 2019, 132, 437-446.	1.5	33
20	Treatment of CD19â€positive mixed phenotype acute leukemia with blinatumomab. American Journal of Hematology, 2019, 94, E7-E8.	4.1	19
21	Acute Onset Unilateral Proptosis. American Journal of Medicine, 2018, 131, e337-e338.	1.5	0
22	High-risk acute promyelocytic leukemia with unusual T/myeloid immunophenotype successfully treated with ATRA and arsenic trioxide-based regimen. Journal of Hematopathology, 2018, $11$ , 67-74.	0.4	5
23	Sickle Cell Disease Complicated by Iron Overload: An Under-Recognized Risk Factor for & lt;b> <i>Vibrio vulnificus</i> Infection. Acta Haematologica, 2018, 139, 199-200.	1.4	4
24	Combination of Blinatumomab and Vincristine Sulfate Liposome Injection for Treatment of Relapsed Philadelphia Chromosome Positive B-cell Acute Lymphoblastic Leukemia. , 2018, 2, .		0